IP Library Granted Patent US 8,138,357
Granted Patent B2
US 8,138,357 · App. 11/989,033 · Granted Mar 20, 2012

Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,138,357
App. No.
11/989,033
Granted
Mar 20, 2012
Kind
B2
Abstract

Therefore the present invention relates specifically to the compounds of general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising H, —C n H 2n-1 , a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R 3 is selected from —CO—CH 3 , —NHOH, —OH, —OR 6 in which R 6 is a linear or branched alkyl group having from 1 to 6 carbon atoms; R 4 is selected from H, a linear or branched alkyl group having from 1 to 6 carbon atoms, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl or allyl; R 5 , R 7 , R 8 are hydrogen atoms; or R 3 and R 4 , R 4 and R 5 , or R 7 and R 8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O. and use thereof in the medical field.

Claims (37)

1. A compound of the general formula (I)

in which

R 1 and R 2 , which may be identical or different, are selected from the group consisting of —H, a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aliphatic ring;

R 3 is selected from, —NHOH, —OH, —OR 6 in which R 6 is a linear or branched alkyl group having from 1 to 6 carbon atoms;

R 7 , R 8 are hydrogen atoms; and

R 4 and R 5 , together form an aliphatic ring, fused to the benzene, with 1 to 2 heteroatoms selected independently from N or O; and salts thereof.

2. A compound as claimed in claim 1 wherein R 1 and R 2 are each independently selected from the group consisting of: —CH 3 , —C 2 H 5 , isopropyl or propyl.

3. A compound as claimed in claim 1 wherein R 4 and R 5 form a ring according to the following formula (III)

4. A compound selected from the group consisting of:

4-amino-N-hydroxy-2-methoxybenzamide,

5-amino-N-hydroxy-2-methoxybenzamide,

5-amino-2,3-dihydrobenzofuran-7-carboxylic acid,

5-amino-2-ethoxy-N-hydroxybenzamide,

5-amino-2-isopropoxybenzoic acid,

and

5-diisopropylaminosalicylic acid.

5. A compound according to claim 1 wherein R 1 and R 2 , are both —CH(CH 3 ) 2 .

6. A compound the represented by the following structure:

and salts thereof.

7. A compound according to claim 1 wherein R 1 and R 2 , are both —H.

8. A compound according to claim 1 represented by the following structure

9. A compound represented by the following structure

10. A compound represented by the following structure

11. A compound represented by the following structure

and salts thereof.

12. A compound represented by the following structure

13. A pharmaceutical composition comprising one or more compounds as defined in claim 1 as active principles in combination with one or more pharmaceutically acceptable excipients or adjuvants.

14. A method of or treating colon tumours expressing the PPARγ receptors and the EGF receptors in a human or animal in need thereof, comprising administering to the human or animal a compound according to claim 1 .

15. A method of treating Crohn's disease or ulcerative rectocolitis in a human or animal in need thereof, comprising administering to the human or animal a compound according to claim 1 .

16. A method of treating Crohn's disease, ulcerative rectocolitis or colon cancer in a human or animal in need thereof, comprising administering to the human or animal a compound selected from the group consisting of 4-amino-N-hydroxy-2-methoxybenzamide, 5-amino-N-hydroxy-2-methoxybenzamide, 5-amino-2,3-dihydrobenzofuran-7-carboxylic acid, 5-amino-2-ethoxy-N-hydroxybenzamide, 6-amino-2,2-dimethyl-4H-benzo[1,3]dioxin-4-one, and salts thereof.

17. A compound represented by (I):

wherein:

R 1 and R 2 , are each independently a linear or branched alkyl group having from 1 to 6 carbon atoms;

R 3 is —NHOH;

R 4 is a linear or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or benzyl; and

R 5 , R 7 , R 8 are hydrogen atoms; and salts thereof.

18. The compound of claim 17 wherein R 4 is selected from the group consisting of —CH 3 , —CH 2 CH 3 and —CH(CH 3 ) 2 .

Assignments (2)
CHANGE OF NAME Recorded Nov 14, 2012
From: GIULIANI INTERNATIONAL LIMITED
To: NOGRA PHARMA LIMITED
Reel/Frame 029295/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2008
From: NACCARI, GIANCARLO; BARONI, SERGIO
To: GIULIANI INTERNATIONAL LIMITED
Reel/Frame 020894/0473 →